We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
Fields »
 

Field

Term
Gene name

Class

Subclass

Chromosome

External id

In atlas

Reliability

Reliability

Reliability

Validation

Method

Validation

Method

Validation

Method

Validation

Location

Searches

Tissue

Cell type

Expression

Tissue

Specificity

Cell line

Specificity

Cancer

Specificity

Tissue

Detectable

Cell line

Detectable

Cancer

Detectable

Cancer

Prognosis

Category

Score

Score

Score

Antibodies

Column

 
 
ABOUT
HELP
BLOG
  • THE HUMAN PROTEOME
  • THE HUMAN TISSUES
  • THE HUMAN CELL
  • HUMAN PATHOLOGY
  • PROTEIN CLASSES
  • PROTEIN EVIDENCE
    • NEWS
    • BLOG
    • EVENTS
    • PRESS ROOM
    • LEARN
    • DICTIONARY
    • METHODS
    • CELL LINES
  • THE PROJECT
  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • PUBLICATION DATA
  • ANTIBODY SUBMISSION
  • ANTIBODY AVAILABILITY
  • LINKS
  • CONTACT
  • TECHNICAL DATA
  • ANTIBODY VALIDATION
  • ASSAYS & ANNOTATION
  • DISCLAIMER
  • DOWNLOADABLE DATA
  • HELP & FAQ
  • LICENCE & CITATION
  • PRIVACY STATEMENT
  • RELEASE HISTORY
ANXA2
  • TISSUE

  • CELL

  • PATHOLOGY

PATHOLOGY ATLAS

GENE/PROTEIN

Antibody validation

Dictionary

Level of antibody staining/expression





High
Medium
Low
Not detected

GENERAL INFORMATION

Gene namei

Gene name according to HGNC.

ANXA2

Gene descriptioni

Gene description according to HGNC.

Annexin A2

Protein classi

Protein class the gene product belongs to according to selected gene lists. List of protein classes.

Cancer-related genes
Plasma proteins
Predicted intracellular proteins
Transporters

Predicted localizationi

Protein localization predicted from several bioinformatic algorithms.

Read more

Intracellular

Number of transcriptsi

Number of protein-coding transcribed from this gene as defined by Ensembl.

27
SHOW MORE

HUMAN PROTEIN ATLAS INFORMATION

RNA categoryi

RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.

TCGA (cancer tissue):Expressed in all
HPA (cell line):Expressed in all
HPA (normal tissue):Expressed in all

Protein evidencei

Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.

Evidence at protein level

Protein expression
normal tissuei

A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.

"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.

Read more

Cytoplasmic staining in several tissues.

ANTIBODY IHC RELIABILITY

Data reliability
descriptioni

Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.

Secreted protein, tissue location of RNA and protein might differ and correlation is complex.

Reliability scorei

Reliability score (score description), divided into Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between the staining pattern of one antibody or several antibodies with RNA-seq data and available gene/protein characterization data.

Read more

Approved based on 1 antibody.
CAB004311
SHOW MORE

PROGNOSTIC SUMMARYi

Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.

Prognostic marker in renal cancer (unfavourable), pancreatic cancer (unfavourable), liver cancer (unfavourable), urothelial cancer (unfavourable), endometrial cancer (favourable) and lung cancer (unfavourable).
Renal cancer p<0.001
Pancreatic cancer p<0.001
Liver cancer p<0.001
Urothelial cancer p<0.001
Endometrial cancer p<0.001
Lung cancer p<0.001
Show all

RNA EXPRESSION OVERVIEWi

RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).

TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name.

Read more
RNA cancer category: Expressed in all

PROTEIN EXPRESSIONi

Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.

For histological reference, visit the histological dictionary.

Colorectal cancer
Breast cancer
Prostate cancer
Lung cancer
Liver cancer

STAINING SUMMARYi

For each cancer, the fraction of samples with protein expression level high, medium, low, or not detected are provided by the blue-scale color-coding (as described by the color-coding scale in the box to the left). The length of the bar represents the number of patient samples analyzed (max=12 patients). The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies. The mouse-over function displays additional data for the features in the staining summary view.

Next to the cancer staining data, the protein expression data of normal tissues or specific cell types corresponding to each cancer are shown and protein expression levels are indicated by the blue-scale color coding.

CAB004311

Cancer

Cancer staining

Protein
expression of
normal tissue

Breast cancer
 
Carcinoid
 
Cervical cancer
 
 
Colorectal cancer
 
 
Endometrial cancer
 
 
Glioma
 
Head and neck cancer
 
 
Liver cancer
 
 
Lung cancer
 
 
Lymphoma
 
 
 

Cancer

Cancer staining

Protein
expression of
normal tissue

Melanoma
 
Ovarian cancer
 
Pancreatic cancer
 
Prostate cancer
 
Renal cancer
 
Skin cancer
 
Stomach cancer
 
 
Testis cancer
 
Thyroid cancer
 
Urothelial cancer
 

Staining summaryi

A manually written summary of the overall protein expression pattern across the analyzed cancer tissues.

Most malignancies showed moderate cytoplasmic positivity. Malignant gliomas were mainly weakly stained or negative.

GENE INFORMATIONi

Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.

Gene name

ANXA2 (HGNC Symbol)

Synonyms

ANX2, ANX2L4, CAL1H, LIP2, LPC2D

Description

Annexin A2 (HGNC Symbol)

Entrez gene summary

This gene encodes a member of the annexin family. Members of this calcium-dependent phospholipid-binding protein family play a role in the regulation of cellular growth and in signal transduction pathways. This protein functions as an autocrine factor which heightens osteoclast formation and bone resorption. This gene has three pseudogenes located on chromosomes 4, 9 and 10, respectively. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

Chromosome

15

Cytoband

q22.2

Chromosome location (bp)

60347134 - 60402883

Protein evidence

Evidence at protein level (all genes)

Ensembl

ENSG00000182718 (version 83.38)

Entrez gene

302

UniProt

P07355 (UniProt - Evidence at protein level)

neXtProt

NX_P07355

Antibodypedia

ANXA2 antibodies

PROTEIN BROWSERi

The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.

At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.

Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50) (read more).

If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.

Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.

«
ANXA2-001
ANXA2-002
ANXA2-005
ANXA2-006
ANXA2-009
ANXA2-010
ANXA2-011
ANXA2-013
ANXA2-016
ANXA2-019
ANXA2-020
ANXA2-021
ANXA2-023
ANXA2-024
ANXA2-025
ANXA2-026
ANXA2-027
ANXA2-028
ANXA2-030
ANXA2-031
ANXA2-032
ANXA2-033
ANXA2-034
ANXA2-035
ANXA2-036
ANXA2-037
ANXA2-038
»

PROTEIN INFORMATIONi

The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.

The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.

The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.

The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.

Splice variant

UniProt

Protein class

Gene ontology

Length & mass

Signal peptide
(predicted)

Transmembrane regions
(predicted)

ANXA2-001
ENSP00000379342
ENST00000396024
P07355 [Direct mapping]
Annexin A2
A0A024R5Z7 [Target identity:100%; Query identity:100%]
Annexin
Show all
Transporters
   Transporter channels and pores
Predicted intracellular proteins
Plasma proteins
Cancer-related genes
   Candidate cancer biomarkers
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001525 [angiogenesis]
GO:0001765 [membrane raft assembly]
GO:0002020 [protease binding]
GO:0002091 [negative regulation of receptor internalization]
GO:0005509 [calcium ion binding]
GO:0005515 [protein binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005546 [phosphatidylinositol-4,5-bisphosphate binding]
GO:0005604 [basement membrane]
GO:0005615 [extracellular space]
GO:0005634 [nucleus]
GO:0005765 [lysosomal membrane]
GO:0005768 [endosome]
GO:0005811 [lipid particle]
GO:0005886 [plasma membrane]
GO:0006900 [membrane budding]
GO:0008092 [cytoskeletal protein binding]
GO:0009986 [cell surface]
GO:0016020 [membrane]
GO:0016323 [basolateral plasma membrane]
GO:0019834 [phospholipase A2 inhibitor activity]
GO:0030496 [midbody]
GO:0030546 [receptor activator activity]
GO:0031012 [extracellular matrix]
GO:0031340 [positive regulation of vesicle fusion]
GO:0031902 [late endosome membrane]
GO:0031982 [vesicle]
GO:0032804 [negative regulation of low-density lipoprotein particle receptor catabolic process]
GO:0036035 [osteoclast development]
GO:0042470 [melanosome]
GO:0043086 [negative regulation of catalytic activity]
GO:0044548 [S100 protein binding]
GO:0044822 [poly(A) RNA binding]
GO:0045121 [membrane raft]
GO:0048306 [calcium-dependent protein binding]
GO:0051290 [protein heterotetramerization]
GO:0070062 [extracellular exosome]
GO:1900121 [negative regulation of receptor binding]
GO:1990667 [PCSK9-AnxA2 complex]
GO:2000273 [positive regulation of receptor activity]
Show all
339 aa
38.6 kDa
No 0
ANXA2-002
ENSP00000387545
ENST00000451270
P07355 [Direct mapping]
Annexin A2
A0A024R5Z7 [Target identity:100%; Query identity:100%]
Annexin
Show all
Transporters
   Transporter channels and pores
Predicted intracellular proteins
Plasma proteins
Cancer-related genes
   Candidate cancer biomarkers
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001525 [angiogenesis]
GO:0001765 [membrane raft assembly]
GO:0002020 [protease binding]
GO:0002091 [negative regulation of receptor internalization]
GO:0005509 [calcium ion binding]
GO:0005515 [protein binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005546 [phosphatidylinositol-4,5-bisphosphate binding]
GO:0005604 [basement membrane]
GO:0005615 [extracellular space]
GO:0005634 [nucleus]
GO:0005765 [lysosomal membrane]
GO:0005768 [endosome]
GO:0005811 [lipid particle]
GO:0005886 [plasma membrane]
GO:0006900 [membrane budding]
GO:0008092 [cytoskeletal protein binding]
GO:0009986 [cell surface]
GO:0016020 [membrane]
GO:0016323 [basolateral plasma membrane]
GO:0019834 [phospholipase A2 inhibitor activity]
GO:0030496 [midbody]
GO:0030546 [receptor activator activity]
GO:0031012 [extracellular matrix]
GO:0031340 [positive regulation of vesicle fusion]
GO:0031902 [late endosome membrane]
GO:0031982 [vesicle]
GO:0032804 [negative regulation of low-density lipoprotein particle receptor catabolic process]
GO:0036035 [osteoclast development]
GO:0042470 [melanosome]
GO:0043086 [negative regulation of catalytic activity]
GO:0044548 [S100 protein binding]
GO:0044822 [poly(A) RNA binding]
GO:0045121 [membrane raft]
GO:0048306 [calcium-dependent protein binding]
GO:0051290 [protein heterotetramerization]
GO:0070062 [extracellular exosome]
GO:1900121 [negative regulation of receptor binding]
GO:1990667 [PCSK9-AnxA2 complex]
GO:2000273 [positive regulation of receptor activity]
Show all
339 aa
38.6 kDa
No 0
ANXA2-005
ENSP00000411352
ENST00000421017
P07355 [Direct mapping]
Annexin A2
A0A024R5Z7 [Target identity:100%; Query identity:100%]
Annexin
Show all
Transporters
   Transporter channels and pores
Predicted intracellular proteins
Plasma proteins
Cancer-related genes
   Candidate cancer biomarkers
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001525 [angiogenesis]
GO:0001765 [membrane raft assembly]
GO:0002020 [protease binding]
GO:0002091 [negative regulation of receptor internalization]
GO:0005509 [calcium ion binding]
GO:0005515 [protein binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005546 [phosphatidylinositol-4,5-bisphosphate binding]
GO:0005604 [basement membrane]
GO:0005615 [extracellular space]
GO:0005634 [nucleus]
GO:0005765 [lysosomal membrane]
GO:0005768 [endosome]
GO:0005811 [lipid particle]
GO:0005886 [plasma membrane]
GO:0006900 [membrane budding]
GO:0008092 [cytoskeletal protein binding]
GO:0009986 [cell surface]
GO:0016020 [membrane]
GO:0016323 [basolateral plasma membrane]
GO:0019834 [phospholipase A2 inhibitor activity]
GO:0030496 [midbody]
GO:0030546 [receptor activator activity]
GO:0031012 [extracellular matrix]
GO:0031340 [positive regulation of vesicle fusion]
GO:0031902 [late endosome membrane]
GO:0031982 [vesicle]
GO:0032804 [negative regulation of low-density lipoprotein particle receptor catabolic process]
GO:0036035 [osteoclast development]
GO:0042470 [melanosome]
GO:0043086 [negative regulation of catalytic activity]
GO:0044548 [S100 protein binding]
GO:0044822 [poly(A) RNA binding]
GO:0045121 [membrane raft]
GO:0048306 [calcium-dependent protein binding]
GO:0051290 [protein heterotetramerization]
GO:0070062 [extracellular exosome]
GO:1900121 [negative regulation of receptor binding]
GO:1990667 [PCSK9-AnxA2 complex]
GO:2000273 [positive regulation of receptor activity]
Show all
339 aa
38.6 kDa
No 0
ANXA2-006
ENSP00000346032
ENST00000332680
P07355 [Direct mapping]
Annexin A2
Show all
Transporters
   Transporter channels and pores
Predicted intracellular proteins
Plasma proteins
Cancer-related genes
   Candidate cancer biomarkers
Protein evidence (Kim et al 2014)
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0001525 [angiogenesis]
GO:0001726 [ruffle]
GO:0001765 [membrane raft assembly]
GO:0001934 [positive regulation of protein phosphorylation]
GO:0002020 [protease binding]
GO:0002091 [negative regulation of receptor internalization]
GO:0005509 [calcium ion binding]
GO:0005515 [protein binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0005546 [phosphatidylinositol-4,5-bisphosphate binding]
GO:0005604 [basement membrane]
GO:0005615 [extracellular space]
GO:0005634 [nucleus]
GO:0005737 [cytoplasm]
GO:0005765 [lysosomal membrane]
GO:0005768 [endosome]
GO:0005769 [early endosome]
GO:0005811 [lipid particle]
GO:0005829 [cytosol]
GO:0005886 [plasma membrane]
GO:0005938 [cell cortex]
GO:0006900 [membrane budding]
GO:0007589 [body fluid secretion]
GO:0008092 [cytoskeletal protein binding]
GO:0009986 [cell surface]
GO:0016020 [membrane]
GO:0016323 [basolateral plasma membrane]
GO:0017137 [Rab GTPase binding]
GO:0019834 [phospholipase A2 inhibitor activity]
GO:0019897 [extrinsic component of plasma membrane]
GO:0030199 [collagen fibril organization]
GO:0030496 [midbody]
GO:0030546 [receptor activator activity]
GO:0031012 [extracellular matrix]
GO:0031340 [positive regulation of vesicle fusion]
GO:0031902 [late endosome membrane]
GO:0031982 [vesicle]
GO:0032804 [negative regulation of low-density lipoprotein particle receptor catabolic process]
GO:0035749 [myelin sheath adaxonal region]
GO:0036035 [osteoclast development]
GO:0042383 [sarcolemma]
GO:0042470 [melanosome]
GO:0042730 [fibrinolysis]
GO:0043086 [negative regulation of catalytic activity]
GO:0043220 [Schmidt-Lanterman incisure]
GO:0043234 [protein complex]
GO:0044354 [macropinosome]
GO:0044548 [S100 protein binding]
GO:0044822 [poly(A) RNA binding]
GO:0045121 [membrane raft]
GO:0048146 [positive regulation of fibroblast proliferation]
GO:0048306 [calcium-dependent protein binding]
GO:0048471 [perinuclear region of cytoplasm]
GO:0051099 [positive regulation of binding]
GO:0051290 [protein heterotetramerization]
GO:0070062 [extracellular exosome]
GO:0072661 [protein targeting to plasma membrane]
GO:0097066 [response to thyroid hormone]
GO:1900121 [negative regulation of receptor binding]
GO:1990667 [PCSK9-AnxA2 complex]
GO:2000273 [positive regulation of receptor activity]
Show all
357 aa
40.4 kDa
No 0
ANXA2-009
ENSP00000453859
ENST00000559818
H0YN42 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
256 aa
28.8 kDa
No 0
ANXA2-010
ENSP00000453039
ENST00000558985
H0YL33 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
142 aa
16.4 kDa
No 0
ANXA2-011
ENSP00000453174
ENST00000559725
H0YLE2 [Direct mapping]
Annexin A2
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
Show all
45 aa
5.3 kDa
No 0
ANXA2-013
ENSP00000453945
ENST00000558169
H0YNB8 [Direct mapping]
Annexin A2
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
47 aa
5.1 kDa
No 0
ANXA2-016
ENSP00000453566
ENST00000559370
H0YMD9 [Direct mapping]
Annexin A2
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
65 aa
7.1 kDa
No 0
ANXA2-019
ENSP00000452895
ENST00000557906
H0YKS4 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
176 aa
19.5 kDa
No 0
ANXA2-020
ENSP00000452858
ENST00000560468
H0YKL9 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
110 aa
12.1 kDa
No 0
ANXA2-021
ENSP00000452981
ENST00000558558
H0YKX9 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
134 aa
14.6 kDa
No 0
ANXA2-023
ENSP00000453841
ENST00000560466
H0YN28 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
139 aa
16.1 kDa
No 0
ANXA2-024
ENSP00000453869
ENST00000559113
H0YN52 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
Show all
59 aa
6.8 kDa
No 0
ANXA2-025
ENSP00000454096
ENST00000558132
H0YNP5 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
Show all
175 aa
19.7 kDa
No 0
ANXA2-026
ENSP00000453694
ENST00000559956
H0YKZ7 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
119 aa
13 kDa
No 0
ANXA2-027
ENSP00000453000
ENST00000559467
H0YKZ7 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
119 aa
13 kDa
No 0
ANXA2-028
ENSP00000453770
ENST00000559780
H0YMW4 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
146 aa
16.2 kDa
No 0
ANXA2-030
ENSP00000453742
ENST00000557986
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
4 aa
0.5 kDa
No 0
ANXA2-031
ENSP00000452921
ENST00000560165
H0YKS4 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
176 aa
19.5 kDa
No 0
ANXA2-032
ENSP00000453556
ENST00000560367
H0YMD0 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
227 aa
25.3 kDa
No 0
ANXA2-033
ENSP00000453925
ENST00000558998
H0YNA0 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
79 aa
9.1 kDa
No 0
ANXA2-034
ENSP00000453579
ENST00000560389
H0YKS4 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
176 aa
19.5 kDa
No 0
ANXA2-035
ENSP00000453739
ENST00000558986
H0YMT9 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
133 aa
14.5 kDa
No 0
ANXA2-036
ENSP00000453663
ENST00000559350
H0YMM1 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
149 aa
16.5 kDa
No 0
ANXA2-037
ENSP00000453464
ENST00000559176
H0YM50 [Direct mapping]
Annexin
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
248 aa
28.3 kDa
No 0
ANXA2-038
ENSP00000452958
ENST00000557904
H0YKV8 [Direct mapping]
Annexin A2
Show all
Predicted intracellular proteins
Protein evidence (Ezkurdia et al 2014)
Show all
GO:0004859 [phospholipase inhibitor activity]
GO:0005509 [calcium ion binding]
GO:0005544 [calcium-dependent phospholipid binding]
GO:0008092 [cytoskeletal protein binding]
GO:0043086 [negative regulation of catalytic activity]
Show all
81 aa
9 kDa
No 0

Contact

  • BLOG
  • PRESS ROOM
  • contact@proteinatlas.org

The Project

  • INTRODUCTION
  • ORGANIZATION
  • PUBLICATIONS
  • DOWNLOADABLE DATA

The Human Protein Atlas

  • ANTIBODY AVAILABILITY
  • LICENCE & CITATION
  • HELP & FAQ
The Human Protein Atlas project is funded
by the Knut & Alice Wallenberg foundation.